Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Elecoglipron

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

AstraZeneca · Phase 1 · Recruiting · Enrollment 152

NCT07723833

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cohort 1-Treatment Sequence An/rn/rn/rn/r
Cohort 1 - Treatment Sequence Bn/rn/rn/rn/r
Cohort 2 - Treatment Sequence Cn/rn/rn/rn/r
Cohort 2 - Treatment Sequence Dn/rn/rn/rn/r
Cohort 3 - Treatment Sequence En/rn/rn/rn/r
Cohort 3 - Treatment Sequence Fn/rn/rn/rn/r
Cohort 4 - Treatment Sequence Gn/rn/rn/rn/r
Cohort 4 - Treatment Sequence Hn/rn/rn/rn/r

Not shown

  • Cohort 1-Treatment Sequence A: endpoint not reported
  • Cohort 1 - Treatment Sequence B: endpoint not reported
  • Cohort 2 - Treatment Sequence C: endpoint not reported
  • Cohort 2 - Treatment Sequence D: endpoint not reported
  • Cohort 3 - Treatment Sequence E: endpoint not reported
  • Cohort 3 - Treatment Sequence F: endpoint not reported
  • Cohort 4 - Treatment Sequence G: endpoint not reported
  • Cohort 4 - Treatment Sequence H: endpoint not reported